Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET XR versus PIOGLITAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET XR versus PIOGLITAZONE.
ACTOPLUS MET XR vs PIOGLITAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTOPLUS MET XR combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating PPAR-γ, and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Selective agonist at peroxisome proliferator-activated receptor-gamma (PPAR-γ), modulating transcription of genes involved in glucose and lipid metabolism, increasing insulin sensitivity in adipose tissue, muscle, and liver.
Initial dose: 15 mg pioglitazone/500 mg metformin hydrochloride extended-release orally once daily with evening meal. Titrate based on glycemic response, maximum dose 45 mg pioglitazone/2000 mg metformin hydrochloride extended-release per day.
15-30 mg orally once daily; maximum dose 45 mg/day.
None Documented
None Documented
Clinical Note
moderatePioglitazone + Gatifloxacin
"Pioglitazone may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderatePioglitazone + Rosoxacin
"Pioglitazone may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderatePioglitazone + Levofloxacin
"Pioglitazone may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderatePioglitazone + Trovafloxacin
"Pioglitazone may increase the hypoglycemic activities of Trovafloxacin."
Pioglitazone: terminal half-life 3-7 hours (parent), 16-24 hours (active metabolites); clinical effect sustained due to metabolites. Metformin: terminal half-life 6.2 hours (plasma), elimination prolonged in renal impairment (creatinine clearance <60 mL/min).
Terminal elimination half-life is 3-7 hours in healthy adults, but extends to 16-24 hours in patients with hepatic impairment due to reduced clearance. Steady-state is achieved after 4-6 days of dosing.
Pioglitazone: predominantly hepatic metabolism, 15-30% excreted in urine as metabolites, ~20% in feces. Metformin: 90% renal excretion unchanged via glomerular filtration and tubular secretion.
Primarily hepatic metabolism via CYP2C8 and CYP3A4; approximately 15-30% excreted in urine as metabolites, with the remainder in feces (~70%) via biliary elimination. Renal excretion of unchanged drug is negligible (<1%).
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione